REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. is a pharmaceutical company that focuses on the clinical development of therapeutic drug candidates. Its primary product candidate in development is brilaroxazine, a chemical compound under evaluation for the treatment of patients with schizophrenia. The company conducts clinical trials to assess the safety and efficacy of this candidate. Because Reviva is currently engaged in drug research and clinical trials, the text identifies no commercial operating segments, and its prospective users are individuals diagnosed with schizophrenia.

The company is incorporated in Delaware and maintains its principal executive offices in Cupertino, California. Reviva conducts its administrative and corporate affairs from this single facility in the United States. The provided text lists no additional offices, retail locations, or international operations. Its operational scope is centered on managing its clinical programs and research activities from its California headquarters.

Summary of the business section of Reviva Pharmaceuticals's latest annual report, written by StockData.

“We have fourteen full-time employees, and utilize consultants, a contract research organization (“CRO”) and third parties to perform our pre-clinical studies, clinical studies, manufacturing, regulatory, administrative, and financial functions.”